Visible-light promoted catalyst-free (VLCF) multi-component synthesis of spiro indolo-quinazolinone-pyrrolo[3,4-a]pyrrolizine hybrids: evaluation of in vitro anticancer activity, molecular docking, MD simulation and DFT studies
- PMID: 37227775
- DOI: 10.1080/07391102.2023.2214229
Visible-light promoted catalyst-free (VLCF) multi-component synthesis of spiro indolo-quinazolinone-pyrrolo[3,4-a]pyrrolizine hybrids: evaluation of in vitro anticancer activity, molecular docking, MD simulation and DFT studies
Abstract
A new and highly efficient visible-light-promoted catalyst free (VLCF) strategy for neat and clean synthesis of spiro indolo-quinazolinone-pyrrolo[3,4-a]pyrrolizine hybrids (6a-d) has been introduced. We have performed visible-light triggered 1,3-Dipolar cycloaddition reaction of maleimide (5a-d) with azomethine ylide generated in situ derived from tryptanthrin (3) and L-proline (4) to obtain desired products (6a-d) in good to excellent yield. Authentication and characterization of product was done using various spectroscopic techniques such as IR, 1H NMR, 13C NMR, Mass spectrometry and single crystal XRD analysis. To explain the reaction spontaneity, product stability, reactivity as well as possible mode of the interaction a quantum chemical investigation was performed and depicted through DFT studies. The synthesized compound 6a was also evaluated for anti-proliferative activity against a panel of five cancer cell lines (MCF-7, MDA-MB-231, HeLa, PC-3 and Ishikawa) and normal human embryonic kidney (HEK-293) cell line by using MTT assay. Compound 6a showed very good in vitro anti-proliferative activity (IC50 = 6.58-17.98 μM) against four cancer cell lines and no cytotoxicity against normal HEK-293. In order to evaluate the anticancer potential of compounds 6a-d, molecular docking was performed against wild type and mutant EGFR. The results suggest that all the compounds occupied the active site of both enzymes, with a strong binding energy (-10.2 to -11.5 kcal/mol). These results have been confirmed by molecular dynamics simulation by evaluating root mean square deviation (RMSD) and root mean square fluctuation (RMSF), along with principal component analysis (PCA).Communicated by Ramaswamy H. Sarma.
Keywords: DFT study; EDA complex; MD simulation; anticancer; azomethine ylide; environment-friendly; molecular docking; spiro-fused; visible-light catalyst-free (VLCF).
Similar articles
-
Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.Comb Chem High Throughput Screen. 2017;20(8):703-712. doi: 10.2174/1386207320666170724110015. Comb Chem High Throughput Screen. 2017. PMID: 28738766
-
Isolation and biological evaluation 7-hydroxy flavone from Avicennia officinalis L: insights from extensive in vitro, DFT, molecular docking and molecular dynamics simulation studies.J Biomol Struct Dyn. 2023 Apr;41(7):2848-2860. doi: 10.1080/07391102.2022.2039771. Epub 2022 Feb 22. J Biomol Struct Dyn. 2023. PMID: 35193476
-
Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1,3,4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors.J Biomol Struct Dyn. 2023 Mar;41(5):1944-1958. doi: 10.1080/07391102.2022.2025906. Epub 2022 Jan 17. J Biomol Struct Dyn. 2023. PMID: 35037830
-
Chemical Characterization, In-silico Evaluation, and Molecular Docking Analysis of Antiproliferative Compounds Isolated from the Bark of Anthocephalus cadamba Miq.Anticancer Agents Med Chem. 2022;22(20):3416-3437. doi: 10.2174/1871520622666220204123348. Anticancer Agents Med Chem. 2022. PMID: 35125087
-
In-vitro anticancer evaluation of newly designed and characterized tri/tetra-substituted imidazole congeners- maternal embryonic leucine zipper kinase inhibitors: Molecular docking and MD simulation approaches.Int J Biol Macromol. 2023 Sep 30;249:126084. doi: 10.1016/j.ijbiomac.2023.126084. Epub 2023 Aug 1. Int J Biol Macromol. 2023. PMID: 37532192
Cited by
-
Natural product-inspired synthesis of coumarin-chalcone hybrids as potential anti-breast cancer agents.Front Pharmacol. 2023 Sep 6;14:1231450. doi: 10.3389/fphar.2023.1231450. eCollection 2023. Front Pharmacol. 2023. PMID: 37745072 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous